MYGN

Myriad Genetics, Inc. - 10-Q Summary (Quarter Ended Sept 30, 2000)

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Myriad Genetics, Inc., covering the three-month period ended September 30, 2000. The company operates in the fields of proteomics and gene-based medicine, focusing on two primary segments: research (gene discovery and therapeutic development) and molecular diagnostics (testing for disease predisposition). As of November 9, 2000, the company had 22,745,459 shares of common stock outstanding.

Key Financial Metrics

Revenue Breakdown: Research revenue was $7,769,251 (up from $5,247,645). Molecular diagnostic revenue was $3,050,009 (up from $1,614,286).

Liquidity: The company holds significant cash and marketable securities ($104.5 million combined), with no long-term debt reported in the balance sheet liabilities.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 58% year-over-year. Molecular diagnostic revenue grew 89%, driven by increased testing volume and wider medical acceptance of tests like BRACAnalysis(R).
• Expense Increases: Research and development expenses rose 52% to $8.79 million due to expanded research activities and drug discovery efforts. Selling, general, and administrative expenses increased 30% to $3.94 million, partly due to preparations for the launch of the COLARIS(TM) test.
• Cash Flow Shift: Operating cash flow turned negative ($5.3 million used) compared to a positive $8.3 million in the prior year. This was primarily due to a $3.8 million decrease in deferred revenue (recognizing previously collected collaborative payments) and increased receivables.
• Financing Activity: The company raised $22.5 million through the private placement of 350,000 shares of common stock in August 2000, significantly boosting liquidity.

Guidance, Outlook, and Risks

Outlook: Management expects to incur losses for at least the next several years due to continued expansion of R&D, drug discovery, and the molecular diagnostic business. The company anticipates existing capital resources will be adequate for at least the next two years but intends to raise additional funds when market conditions are favorable.

New Developments: The company launched COLARIS(TM), a predictive medicine test for hereditary colon and uterine cancer, in September 2000. A subsequent event noted a $41 million private placement of stock on October 27, 2000.

Risks and Contingencies:

• Uncertainty regarding reimbursement from government and private insurers for genetic testing services.
• Intense competition in gene discovery and the risk that competitors may secure rights to important genes.
• Regulatory uncertainties and the risk that therapeutic products may not achieve commercial acceptance.
• Dependence on collaborative agreements (e.g., with Bayer, Schering, Pharmacia) for a significant portion of funding and future royalties.

Investor Verification Checklist

• Deferred Revenue Recognition: Verify the sustainability of revenue growth given the $3.8 million drawdown in deferred revenue, which indicates recognition of past payments rather than new cash inflows.
• Operating Cash Burn: Confirm the company's ability to sustain operations with negative operating cash flow of $5.3 million, despite strong financing inflows.
• Collaboration Dependencies: Assess the terms and renewal risks of major partnerships (Bayer, Schering, Pharmacia) which drive a large portion of research revenue.
• Diagnostic Reimbursement: Investigate the status of insurance reimbursement for new tests like COLARIS(TM) and BRACAnalysis(R), as this is a cited risk factor.
• Subsequent Financing: Note the $41 million capital raise in October 2000 and its impact on dilution and future runway.